Phase 2 Hepatocellular Carcinoma (HCC) Clinical Trials
42 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 42 trials
Recruiting
Phase 1Phase 2
A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
Advanced or Unresectable Hepatocellular Carcinoma (HCC)
Huahui Health30 enrolled21 locationsNCT07547553
Recruiting
Phase 2
Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC
Hepatocellular Carcinoma (HCC)
Shunda Du32 enrolled1 locationNCT07639138
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Hepatocellular Carcinoma (HCC)
Bristol-Myers Squibb198 enrolled59 locationsNCT07291076
Recruiting
Phase 2
Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus
Hepatocellular Carcinoma (HCC)Portal Vein Tumor Thrombus
First Hospital of China Medical University38 enrolled1 locationNCT07483359
Recruiting
Phase 2
Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy
Hepatocellular Carcinoma (HCC)
CHA University80 enrolled1 locationNCT07493668
Recruiting
Phase 2
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC)
Tianjin Medical University Cancer Institute and Hospital30 enrolled1 locationNCT07012798
Recruiting
Phase 2
Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC)
Tongji Hospital94 enrolled1 locationNCT07413354
Recruiting
Phase 2
A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
Hepatocellular Carcinoma (HCC)
Second Affiliated Hospital, School of Medicine, Zhejiang University36 enrolled1 locationNCT07422753
Recruiting
Phase 2
HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
Hepatocellular Carcinoma (HCC)
Fudan University164 enrolled1 locationNCT06860490
Recruiting
Phase 2Phase 3
A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
Hepatocellular Carcinoma (HCC)
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.680 enrolled2 locationsNCT07490262
Recruiting
Phase 1Phase 2
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
Hepatocellular Carcinoma (HCC)
RayzeBio, Inc.590 enrolled13 locationsNCT06726161
Recruiting
Phase 2Phase 3
Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)
Hepatocellular Carcinoma (HCC)
Tuen Mun Hospital106 enrolled1 locationNCT07293468
Recruiting
Phase 2
Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
Hepatocellular Carcinoma (HCC)
Ruijin Hospital35 enrolled4 locationsNCT07331883
Recruiting
Phase 2
HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma
Advanced Hepatocellular Carcinoma (HCC)
Sun Yat-sen University76 enrolled1 locationNCT06737913
Recruiting
Phase 1Phase 2
Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
Metastatic Liver CancerAdvanced Hepatocellular Carcinoma (HCC)
Beijing Biotech30 enrolled1 locationNCT07500220
Recruiting
Phase 1Phase 2
A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection
Hepatocellular Carcinoma (HCC)
Yinghua Xu20 enrolled1 locationNCT07495215
Recruiting
Phase 2
Phase 2 Study of WGI-0301 for Advanced HCC
Advanced Hepatocellular Carcinoma (HCC)
Zhejiang Haichang Biotech Co., Ltd.60 enrolled4 locationsNCT06309485
Recruiting
Phase 2
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
Hepatocellular Carcinoma (HCC)
Akeso100 enrolled1 locationNCT07052253
Recruiting
Phase 2
Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcinoma With High-risk Recurrence Factors
Hepatocellular Carcinoma (HCC)
Northern Jiangsu People's Hospital30 enrolled1 locationNCT07337421
Recruiting
Phase 2
Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors
Hepatocellular Carcinoma (HCC)
Northern Jiangsu People's Hospital30 enrolled1 locationNCT07337460